NRDS heads into after-hours trading on the back of a mixed Q1 print — EPS beat, revenue missed, and a conservative Q2 guide that the market will need to digest.
NerdWallet reported Q1 EPS of $0.29, clearing the $0.25 consensus estimate. Revenue of $222.2M fell short of the $228.1M the Street was looking for. More tellingly, Q2 sales guidance of $186M–$202M landed well below the $205.2M analyst estimate. For a stock that rallied 16% in a single day after its February earnings print, the setup heading into tomorrow's open is notably softer. Headlines after the close described the stock as dropping despite the strong profitability showing — the gap between bottom-line discipline and top-line pressure is the core tension here.
Short interest going into this print was already elevated, running at roughly 16.5% of the free float — well down from the 21% level seen in mid-March but still a meaningful overhang. Bears have been stepping back: shorts fell sharply through April, dropping from above 5.5 million shares in early April to around 4.5 million by month-end, a 19% reduction over 30 days. Borrow costs tell the same low-pressure story, with the cost to borrow easing to 0.48% — a fraction of what it was just six weeks ago, and down a third on the month. Availability is not a constraint here. The ORTEX short score of 60.9 reflects a moderately elevated position, but the direction of travel through April was clear cover, not build.
Options traders read the outcome more accurately than the bears did. The put/call ratio eased to 0.80 heading into the print — roughly one standard deviation below its 20-day average of 0.98. After spending much of March and early April above 1.5, with peak readings near 1.9 in late March, the ratio compressed sharply through April as the macro noise faded and the stock clawed back 4.7% on the month. That shift from heavy downside protection toward a more neutral posture set up the options market for a miss on guidance rather than an outright blow-up.
The Street's posture is mixed heading into the reaction. The consensus sits at Hold, with Morgan Stanley the most notable recent mover — James Faucette downgraded the stock to Underweight and cut his target to $9 back in mid-March, the most bearish call on the register. Oppenheimer and Truist both maintain positive ratings (Outperform and Buy respectively) but both trimmed targets after the February results, landing at $15 and $18. The mean price target of $14.50 implies roughly 33% upside to Tuesday's close of $10.89 — but that figure now looks stale given the guide, and further target cuts from the bull camp seem plausible after today. Valuation multiples remain cheap in absolute terms: the EV/EBITDA multiple is around 4.5x and the P/E sits below 7x. EPS momentum ranks in the 81st percentile on a 30-day basis, reflecting the series of beats — but the gap between earnings momentum and revenue trajectory is a structural question the bulls will need to answer.
The last comparable print — February's Q4 2025 results — sent the stock up 15.8% the next day and 16.8% over the following week, driven by an EPS beat and stronger-than-expected momentum in key verticals. Tonight's setup is materially different: EPS beat again, but the revenue miss and below-consensus Q2 guide introduce the kind of uncertainty that pushed the PCR to 1.9 in late March in the first place. Correlated peers were mixed on the week — SOFI fell 12.7% and TREE dropped 19.3%, suggesting the broader consumer finance and fintech-adjacent universe faced its own headwinds — while OPFI bucked the trend with an 8.2% gain. NRDS underperformed on the week with a 1.7% decline before the print.
The key watch point from here is how the Street re-rates around the Q2 guide — specifically whether the bulls at Oppenheimer and Truist trim targets again, or whether the EPS-over-revenue thesis holds enough to keep positive ratings intact into the back half of the year.
See the live data behind this article on ORTEX.
Open NRDS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
